Curt A. Ries, MD

Johns Hopkins University, 1957-1960, Biological Sciences
University of Rochester School of Medicine, M.D., 1960-1964, Medicine

• 1964-1965
  Intern in Medicine, Strong Memorial Hospital, Rochester, NY
• 1965-1966
  Assistant Resident in Medicine, Strong Memorial Hospital, Rochester, NY
• 1968-1969
  Resident in Medicine (II), University of California Hospitals, San Francisco, CA
• 1969-1970
  Chief Resident in Medicine, University of California Hospitals (San Francisco General Hospital), San Francisco, CA
• 1970-1972
  Fellow in Hematology, University of California, San Francisco, CA
• 1972-1976
  Assistant Clinical Professor of Medicine, Laboratory Medicine, and Radiology (Nuclear Medicine), University of California, San Francisco, CA
• 1972-1974
  Chief, Hematology Clinic, University of California Medical Center, San Francisco, CA
• 1974-1980
  Director, Hematology & Oncology Clinics, University of California Medical Center, San Francisco, CA
• 1976-1983
  Associate Clinical Professor of Medicine and Laboratory Medicine, University of California, San Francisco, CA
• 1989-1991
  Director, Adult Bone Marrow Transplant Program, University of California Medical Center, San Francisco, CA
• 1975-2002
  Director, Outpatient Transfusion Service, University of California Medical Center, San Francisco, CA
• 1980-2002
  Director, Hematology/Oncology Faculty Practice, University of California Medical Center, San Francisco, CA
• 1983-2003
  Clinical Professor of Medicine, University of California, San Francisco, CA
• 2003-present
  Clinical Professor of Medicine Emeritus, University of California, San Francisco, CA

• Edward Ageno Distinguished Professor of Hematology Oncology, UCSF

• Smith GA, Damon LE, Rugo HS, Ries CA, & Linker CA: High-dose Ara-C (HDAC) dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833, 1997.
• Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 22:865-872, 1998.
• Linker CA, Ries CA, Damon LE, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolf J. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biology of Blood and Marrow Transplantation 6(1):50-57 (2000).
• Damon LE, Wolf JL, Rugo HS, Gold E, Ries CA, Zander AR, Tracy M, Cecchi G, Irwin D, & Linker CA: High-dose chemotherapy for breast cancer: Improved results in patients with ten or more involved axillary lymph nodes. Bone Marrow Transpl Aug;26(3): 257-268, 2000.
• Linker CA, Damon LE, Ries CA, Navarro W, Case D, Wolf J. Autologous stem cell transplant for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb;29(4):297-301.
• Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002 May 15;20 (10):2464-71.